Arcus sets the hopes for Tigit in lung cancer
As biopharma awaits Roche’s pivotal Skyscraper-01 data Arcus gives its investors some more tea leaves to read.
Asset resuscitation fails to resuscitate Mereo
Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
Close encounters of the Serd kind
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
Lilly takes on Novo in obesity
Tirzepatide is coming for Wegovy’s crown – and maybe faster than expected.
Protagonist “delighted” with trial failure
Development of the ulcerative colitis project PN-943 continues.
Nkarta: at least as good as Fate, at a tenth of the price
After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.
